While technological breakthroughs of the last decade have greatly advanced our understanding of the cancer genome, they have also revealed the immense complexity and heterogeneity of tumors. The key to further advancing our understanding and treatment of cancer is to distinguish between genes and pathways that drive tumorigenesis (driver events) and neutral, passenger events. A growing body of evidence has shown that not all DNA-level alterations have biological implications, making it necessary to examine multiple ꞌomics levels including the transcriptome and proteome, to identify critical driver events. In this webinar, our expert panel will discuss how using a multi-omics–based approach to cancer research can advance our understanding of cancer biology as well as lead to the discovery of novel biomarkers.
During the webinar, the speakers will:
- Discuss how analyzing multi-omics data, such as copy number alteration and coding and noncoding RNA expression, can lead to more rapid identification and prioritization of cancer driver events
- Explain how advancements in technologies that are sensitive enough to detect all-important genetic and transcriptomic changes are driving the discovery of novel biomarkers
- Present the advantages of examining multiple versus single analytes to explain diagnostic, prognostic, and predictive outcomes
- Answer your questions live during the broadcast!
The webinar will last approximately 60 minutes.
To learn more about products or technologies related to this webinar,
go to: www.affymetrix.com/translational